CClinicalTrials.gg
Not yet recruitingNCT07594223Updated May 18, 2026

Efficacy of Activator Trigger Point and Shock Wave Therapy on Pain and Function in Active Upper Trapezius Trigger Points: A Randomized Controlled Study

An interventional study of Shockwave and Activator in Cervical, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 27 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
27 Years to 40 Years
Sex
All
01

Study summary

This study will be conducted as a randomized controlled trial to evaluate the efficacy of trigger point activator and extracorporeal shock wave therapy in patients with active myofascial trigger points in the upper fibers of the trapezius muscle. Participants who meet the inclusion criteria will be recruited and informed consent will be obtained prior to participation. The subjects will then be randomly allocated into two equal groups. Group A: will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle. Group B: will receive extracorporeal shock wave therapy applied to the same region.

The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period. Outcome measures will be assessed before the beginning of the treatment program and after completion of the intervention period. Pain intensity and pressure pain threshold will be assessed using an algometer. Functional disability related to the neck will be evaluated using the Neck Disability Index (NDI). All collected data will be recorded and statistically analyzed to determine the effectiveness of both treatment modalities in reducing pain and improving functional outcomes.

Read the detailed description

This study will be conducted as a randomized controlled trial to evaluate the efficacy of trigger point activator and extracorporeal shock wave therapy in patients with active myofascial trigger points in the upper fibers of the trapezius muscle. Participants who meet the inclusion criteria will be recruited and informed consent will be obtained prior to participation. The subjects will then be randomly allocated into two equal groups. Group A: will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle. Group B: will receive extracorporeal shock wave therapy applied to the same region.

The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period. Outcome measures will be assessed before the beginning of the treatment program and after completion of the intervention period. Pain intensity and pressure pain threshold will be assessed using an algometer. Functional disability related to the neck will be evaluated using the Neck Disability Index (NDI). All collected data will be recorded and statistically analyzed to determine the effectiveness of both treatment modalities in reducing pain and improving functional outcomes. 15. Participants of the study:

  1. The number of participants: 200 (50 per group to ensure 40 completers per arm after attrition).
  2. Important characteristics

    • Adult (27:40 years):
    • Gender: both gender
    • Diagnosis: Active upper trapezius trigger points Inclusion criteria

      1. Male or female participants aged between 25 and 40 years.
      2. Body Mass Index (BMI) between 20 and 30 kg/m².
      3. Presence of active myofascial trigger points in the upper fibers of the trapezius muscle confirmed by clinical examination.
      4. Complaints of neck pain associated with upper trapezius trigger points.
      5. Ability and willingness to participate in the treatment sessions and follow the study protocol.

Exclusion criteria:

  1. History of neck trauma, cervical spine fracture, or cervical spine surgery.
  2. Presence of neurological disorders affecting the cervical region.
  3. Presence of cervical disc prolapse or severe cervical spine pathology.
  4. Diagnosis of fibromyalgia or systemic musculoskeletal disorders.
  5. Presence of skin diseases, wounds, or infections at the treatment area.
  6. Patients with malignancy or severe systemic diseases.
02

Conditions studied

  • Cervical

Keywords

  • cervical
  • trigger points
  • shock wave
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
27 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 1. Male or female participants aged between 25 and 40 years. 2. Body Mass Index (BMI) between 20 and 30 kg/m². 3.Presence of active myofascial trigger points in the upper fibers of the trapezius muscle confirmed by clinical examination.

    • Complaints of neck pain associated with upper trapezius trigger points. 5. Ability and willingness to participate in the treatment sessions and follow the study protocol.

Exclusion criteria

Exclusion Criteria:

  • 1. History of neck trauma, cervical spine fracture, or cervical spine surgery. 2. Presence of neurological disorders affecting the cervical region. 3. Presence of cervical disc prolapse or severe cervical spine pathology. 4. Diagnosis of fibromyalgia or systemic musculoskeletal disorders. 5. Presence of skin diseases, wounds, or infections at the treatment area. 6. Patients with malignancy or severe systemic diseases.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    treatment

    receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle.

    Device: Activator

  • Active comparator
    Shockwave

    will receive extracorporeal shock wave therapy applied to the same region. The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period.

    Device: Shockwave

Interventions

  • DeviceShockwave

    will receive extracorporeal shock wave therapy applied to the same region. 12. The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period.

  • DeviceActivator

    will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle.

06

What researchers measure

Primary outcomes

  1. Neck Disability Index (NDI)

    Questionnaire assessing neck function valid and reilable

    Time frame: 6 weeks

  2. VAS

    Pain score

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07594223
Lead sponsor
Cairo University
Collaborators
Suez University
Responsible party
Mina Magdy Wahba (Department of Physical Therapy for Orthopedics, Faculty of Physical Therapy, Suez University) — Principal investigator
First posted
May 18, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Nov 12, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 18, 2026

Study contacts

Mina Wahba, phD
Contact
mina.magdy@the.suezuni.edu.eg
+062 3707068

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion